Developer docs
API playgroundTry for free, no card

Search company profiles

TaiMed Biologics

Full company profile

uuid0009tie

Namestring
TaiMed Biologics
Legal namestring
中裕新藥股份有限公司
Company typeenum
Public
Founded yearint
2007
Descriptiontext

TaiMed Biologics (TPEX: 4147) is a Taiwan-based, publicly traded commercial-stage biopharmaceutical company founded in 2007 that develops monoclonal antibody therapeutics for HIV disease. Its flagship commercial product, Trogarzo (ibalizumab), is the world's first and only FDA-approved monoclonal antibody for HIV treatment (approved 2018), acting as a post-attachment inhibitor that binds the CD4 receptor. The company's proprietary technology platform centers on CD4-targeted antibody engineering, including the LM52 glycan modification and histidine modification technologies (patent-protected until 2040) that underpin its second-generation pipeline candidate TMB-365, as well as a first-in-class antibody-drug conjugate (ADC) platform targeting CD4+ T cells. The pipeline lead, TMB-365/TMB-380, is a long-acting dual antibody combination currently in Phase 2b clinical development for first-line HIV maintenance therapy, with FDA Fast Track Designation and peak sales potential estimated up to US$4 billion.

TaiMed operates an asset-light, partnership-driven business model. It generates product revenue through exclusive regional licensing and distribution partners — Theratechnologies (US/Canada), AcedrA (MENA), Wuzhou (Hong Kong/Macau), Orient EuroPharma (Taiwan), Helios (Vietnam), Slim Pharmaceuticals (Sri Lanka), and R-Pharm (Russia) — rather than building its own global salesforce. It also offers contract development and manufacturing (CDMO) services from its cGMP facility in Zhubei, Taiwan (bioreactors 50L-2000L, passed FDA inspections in 2022 and 2023 with zero 483 observations), and signed its first international US CDMO client in October 2024. The company is positioning for global licensing transactions on its TMB-365/380 combination, supported by a NT$1.64 billion capital raise in Q1 2024 and an approved private placement to strategic investors.

Financially, TaiMed reported H1 2024 operating revenue of NT$325.9M (~85% YoY growth) with net cash inflow of NT$76.7M, and H1 2024 cash balance of NT$2.1 billion. The company is led by CEO Dr. Jimmy Chang and was co-founded with David Ho's Aaron Diamond AIDS Research Center; it is included in the MSCI Small Cap Index and recently received Taiwan's 22nd National Innovation Award (2025) for TMB-365/380.

Short descriptiontext

TaiMed Biologics is a Taiwan-based, publicly traded biopharmaceutical company developing monoclonal antibody therapeutics for HIV, commercializing the first FDA-approved mAb for HIV (Trogarzo) and advancing a long-acting dual antibody pipeline through Phase 2b trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersTaipei, Taiwan
HQ citystring
Taipei
HQ countrystring
Taiwan
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
monoclonal antibody therapeutics, HIV treatment biologics, antibody-drug conjugates, CDMO biologics manufacturing, long-acting HIV therapy
Industry4 codes
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAKAGAB
HIV/AIDS Medicine
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
HIV Therapeutics Biologics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Trogarzo Product Sales
TypeLicensing Royalties
Description

Revenue from global sales of Trogarzo (ibalizumab) through licensing and distribution partnerships in various territories including US, Europe, MENA, Asia regions.

taimedbiologics.com
2CDMO Services
TypeProfessional Services
Description

Contract development and manufacturing organization services providing cGMP manufacturing, process development, analytical method development and validation, formulation development, and monoclonal antibody stability testing for pharmaceutical clients.

taimedbiologics.com
3Licensing and Co-development Agreements
TypeLicensing Royalties
Description

Revenue from licensing TMB-365/380 technology and potential co-development partnerships with global pharmaceutical companies for long-acting HIV therapy.

taimedbiologics.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels9 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Trogarzo
Description

First humanized monoclonal antibody (mAb) developed for the treatment of HIV-1 infection, approved by US FDA in 2018

taimedbiologics.com
+1 more record
Core offering1 text field

TaiMed Biologics develops and commercializes monoclonal antibody therapeutics for HIV disease. Its commercial product Trogarzo (ibalizumab) is the world's first humanized monoclonal antibody approved by the US FDA for the treatment of multidrug-resistant HIV-1 infection. The company is advancing TMB-365/TMB-380, the world's first long-acting dual antibody HIV therapy administered every 8 weeks, and a CD4-targeted ADC platform. It also provides biologics CDMO services from its cGMP facility in Taiwan.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 94% of participants maintained HIV-1 RNA below 50 copies/mL at Week 24 in Phase 2a trial
+4 more records
Product overview1 text field

TaiMed Biologics is a commercial-stage biopharmaceutical company that has developed and commercialized Trogarzo® (ibalizumab), the world's first and only FDA-approved monoclonal antibody for HIV treatment. The company offers two formulations of Trogarzo: IV Infusion and IV Push. Its pipeline includes TMB-365, a second-generation antibody, TMB-380, a broadly neutralizing antibody, and their combination therapy TMB-365/TMB-380 (currently in Phase 2b), representing the world's first long-acting dual antibody HIV therapy. The company is also developing an innovative Antibody-Drug Conjugate (ADC) platform for HIV treatment. In addition to its proprietary products, TaiMed provides comprehensive CDMO (Contract Development and Manufacturing Organization) services from its cGMP facility in Taiwan.

Product and service7 records
1Trogarzo (ibalizumab)
CategoryHIV Therapeutics / Monoclonal Antibody
Description

The world's first humanized monoclonal antibody (mAb) approved for the treatment of HIV-1 infection. Acts as a post-attachment inhibitor by binding to the second extracellular domain of the CD4 receptor, blocking HIV entry while preserving immune function. Indicated for heavily treatment-experienced adults with multidrug-resistant (MDR) HIV-1 infection.

2Trogarzo IV Infusion
CategoryHIV Therapeutics / Monoclonal Antibody
Description

Intravenous infusion formulation of Trogarzo administered every two weeks for the treatment of HIV multi-drug-resistant patients as a last-line therapy.

3Trogarzo IV Push
CategoryHIV Therapeutics / Monoclonal Antibody
Description

Rapid intravenous push administration option of Trogarzo approved by the FDA for both loading dose (2000mg) and maintenance dose (800mg), offering convenient administration in undiluted form.

4TMB-365
CategoryHIV Therapeutics / Pipeline Biologic
Description

Second-generation Trogarzo monoclonal antibody for HIV treatment and prevention. Exhibits enhanced potency, viral coverage, and half-life. Developed from CD4-targeted antibody technology licensed from Aaron Diamond AIDS Research Center with TaiMed holding exclusive global rights.

5TMB-365/TMB-380 Combination
CategoryHIV Therapeutics / Pipeline Biologic
Description

Long-acting dual monoclonal antibody combination for HIV maintenance therapy combining TMB-365 and TMB-380. Administered as a single IV infusion every 8 weeks as a complete regimen. No susceptibility screening required before initiation and zero drug-drug interactions due to antibody-based mechanism not metabolized through liver.

6CD4-Targeted Antibody-Drug Conjugates (ADCs)
CategoryADC Platform / HIV Therapeutics
Description

Precision targeting ADC technology combining monoclonal antibodies with high binding specificity to CD4+ T cells with antiretroviral drug payloads. Triple-action mechanism: serves as carrier for antiretroviral drugs, acts as HIV entry inhibitor, and provides precision antiretroviral activity. First-in-Class ADC platform for HIV treatment.

7Biologics CDMO Services
CategoryContract Manufacturing Services
Description

Contract Development and Manufacturing Organization services providing cGMP manufacturing, process development, analytical method development and validation, formulation development, and monoclonal antibody stability testing. Uses single-use technology with bioreactors from 50L to 2000L capacity at the Zhubei facility in Taiwan.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership16 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-22
Description

Supply agreement for pharmaceutical ingredients for TMB-365, a long-acting biologic candidate currently in development. Collaboration supports continued development and manufacturing needs of TMB-365, following TaiMed's completion of Phase 2b enrollment for TMB-365/380.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-01
Description

Post-Approval Named Patient Program supply agreement for Trogarzo in Russia, providing access for patients with limited treatment options.

3National Taiwan University (NTU) School of Pharmacy
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-06-10
Description

MOU for internship and talent development program. 16-week internship program at TaiMed facilities equivalent to 13 academic credits, providing hands-on exposure to biotechnology and biopharmaceutical industries.

taimedbiologics.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-03-06
Description

Strategic collaboration for commercialization of Trogarzo in Vietnam. Leading pharmaceutical local distributor committed to advancing patient access to innovative medicines and aligning Vietnam's healthcare system with global standards.

5Marigold Therapeutics
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-03-05
Description

Strategic investment in Marigold Therapeutics to advance ADC drug development. Marigold has core ADC technology platform with founding team experienced in ADC molecule development. Headquartered in Cayman Islands with R&D team being built in Taiwan.

taimedbiologics.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-02-24
Description

Exclusive license agreement for Trogarzo in Sri Lanka. Leading distributor of high-quality pharmaceuticals established in 2011, headquartered in Sri Lanka.

7US-based Biotechnology Client
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2024-10-29
Description

First international CDMO contract from US client for manufacturing antibody drug for clinical trials. Demonstrates international recognition of TaiMed's CDMO service capabilities.

taimedbiologics.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-05-20
Description

Exclusive license agreement for Trogarzo commercialization in Taiwan. OEP pursues regulatory approval and commercial sales. Established in 1982, listed on Taiwan GreTai Securities Market (stock code: 4120), with global workforce exceeding 1,000 employees.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-05-10
Description

Exclusive license agreement for Trogarzo in Hong Kong and Macau. Macau pharmaceutical company that has introduced more than ten blockbuster products into China within five years. BLA submitted to regulatory authorities.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-03-14
Description

Exclusive license, commercialization and distribution agreement for Trogarzo in Middle East and North Africa region (Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Jordan, Egypt, Lebanon, Iraq, Libya, Tunisia, Algeria, Morocco, Sudan). Saudi-based company focused on orphan drugs and niche therapeutic segments.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-01-01
Description

Named Patient Program (NPP) collaboration for Trogarzo in Europe and regions beyond US and Canada. Professional services company helping patients obtain medications when no other treatment options are available.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Exclusive marketing partner for Trogarzo in United States and Canada. Partnership continues despite announcement of Future Pak acquisition of Theratechnologies expected to close Q4 2025.

13Aaron Diamond AIDS Research Center (ADARC)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Technology licensing for CD4-targeted antibody technology platform used in TMB-365 development. Led by Dr. David Ho.

taimedbiologics.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Non-exclusive licensing agreement from NIAID for TMB-380 (VRC07-523LS), a broadly neutralizing HIV-1 antibody. NIH conducted successful Phase 1 trial demonstrating efficacy in HIV patients receiving bi-monthly IV infusion.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research partnership for HIV antibody development and technology advancement.

16Tanvex BioPharma Inc
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration with biotech and medical institutions for research and development of technologies promoting human well-being.

taimedbiologics.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Majority-owned by GSK, ViiV is the leading global HIV-focused pharmaceutical company with long-acting injectables like Cabenuva (cabotegravir/rilpivirine) and Apretude. It is the most direct competitor to TaiMed's TMB-365/380 in the long-acting HIV maintenance therapy space.

TypeEmerging player
Description

Clinical-stage biotech developing leronlimab, a CCR5-targeting mAb, for HIV and other indications. CytoDyn is an emerging mAb-focused HIV therapeutic developer with comparable niche positioning, though with different mechanism and clinical profile.

TypeBroad incumbent
Description

Diversified biopharmaceutical company with a strong immunology and infectious disease portfolio. AbbVie's expertise in mAb development and commercialization (Humira, Skyrizi) makes it a relevant peer and potential acquirer for TaiMed's mAb platform.

TypeBroad incumbent
Description

Largest HIV franchise globally with Biktarvy, Descovy, and the recently approved long-acting capsid inhibitor lenacapavir (Sunlenca). Gilead is both a competitor in long-acting HIV and a potential acquirer/licensor for TaiMed's TMB-365/380 platform.

TypeBroad incumbent
Description

Major HIV therapy player with doravirine (Pifeltro) and ongoing development of once-monthly oral islatravir combinations. Merck's combination therapies compete in the same maintenance therapy market TaiMed targets with TMB-365/380.

TypeOthers
Description

Global CDMO partner for TaiMed's TMB-365 supply. Samsung Biologics is one of the world's largest contract manufacturers and a relevant peer in the CDMO services space where TaiMed increasingly competes.

TypeDirect peer
Description

Exclusive marketing partner for Trogarzo in US/Canada. Theratechnologies is a specialty HIV-focused company developing Trogarzo and other HIV therapeutics, with deep domain overlap though it functions as a commercial rather than R&D peer for TaiMed.

TypeBroad incumbent
Description

Largest global CDMO with extensive biologics manufacturing capabilities. Lonza is a relevant peer for TaiMed's growing CDMO business, providing scale benchmarks in cGMP contract manufacturing for monoclonal antibodies.

TypeBroad incumbent
Description

Leading global biologics CDMO providing end-to-end mAb development and manufacturing services. WuXi is a direct competitor for TaiMed's CDMO service business and shares exposure to mAb manufacturing scale-up.

TypeBroad incumbent
Description

Leading mAb development platform (VelocImmune) with deep expertise in antibody engineering, similar to TaiMed's proprietary antibody engineering capabilities (LM52 glycan, histidine modification). Relevant as a technology platform peer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TaiMed Biologics

HIV Therapeutics Biologicstaimedbiologics.com

TaiMed Biologics is a Taiwan-based, publicly traded biopharmaceutical company developing monoclonal antibody therapeutics for HIV, commercializing the first FDA-approved mAb for HIV (Trogarzo) and advancing a long-acting dual antibody pipeline through Phase 2b trials.

What TaiMed Biologics does

TaiMed Biologics (TPEX: 4147) is a Taiwan-based, publicly traded commercial-stage biopharmaceutical company founded in 2007 that develops monoclonal antibody therapeutics for HIV disease. Its flagship commercial product, Trogarzo (ibalizumab), is the world's first and only FDA-approved monoclonal antibody for HIV treatment (approved 2018), acting as a post-attachment inhibitor that binds the CD4 receptor. The company's proprietary technology platform centers on CD4-targeted antibody engineering, including the LM52 glycan modification and histidine modification technologies (patent-protected until 2040) that underpin its second-generation pipeline candidate TMB-365, as well as a first-in-class antibody-drug conjugate (ADC) platform targeting CD4+ T cells. The pipeline lead, TMB-365/TMB-380, is a long-acting dual antibody combination currently in Phase 2b clinical development for first-line HIV maintenance therapy, with FDA Fast Track Designation and peak sales potential estimated up to US$4 billion.

TaiMed operates an asset-light, partnership-driven business model. It generates product revenue through exclusive regional licensing and distribution partners — Theratechnologies (US/Canada), AcedrA (MENA), Wuzhou (Hong Kong/Macau), Orient EuroPharma (Taiwan), Helios (Vietnam), Slim Pharmaceuticals (Sri Lanka), and R-Pharm (Russia) — rather than building its own global salesforce. It also offers contract development and manufacturing (CDMO) services from its cGMP facility in Zhubei, Taiwan (bioreactors 50L-2000L, passed FDA inspections in 2022 and 2023 with zero 483 observations), and signed its first international US CDMO client in October 2024. The company is positioning for global licensing transactions on its TMB-365/380 combination, supported by a NT$1.64 billion capital raise in Q1 2024 and an approved private placement to strategic investors.

Financially, TaiMed reported H1 2024 operating revenue of NT$325.9M (~85% YoY growth) with net cash inflow of NT$76.7M, and H1 2024 cash balance of NT$2.1 billion. The company is led by CEO Dr. Jimmy Chang and was co-founded with David Ho's Aaron Diamond AIDS Research Center; it is included in the MSCI Small Cap Index and recently received Taiwan's 22nd National Innovation Award (2025) for TMB-365/380.

TaiMed Biologics firmographics

Firmographics
Name
TaiMed Biologics
Legal name
中裕新藥股份有限公司
Website
https://taimedbiologics.com
Company type
Public
Founded year
2007
Operating status
Operating
Headcount range
51–100 employees
Short description
TaiMed Biologics is a Taiwan-based, publicly traded biopharmaceutical company developing monoclonal antibody therapeutics for HIV, commercializing the first FDA-approved mAb for HIV (Trogarzo) and advancing a long-acting dual antibody pipeline through Phase 2b trials.
Ownership category
akta.pro rank

TaiMed Biologics industry classification

Industry
Product category
HIV Therapeutics Biologics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAKAGAB
HIV/AIDS Medicine
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)

Keywords

  • Monoclonal antibody therapeutics
  • HIV treatment biologics
  • Antibody-drug conjugates
  • CDMO biologics manufacturing
  • Long-acting HIV therapy

Where TaiMed Biologics is headquartered

Location

Headquarters

HQ city
Taipei
HQ country
Taiwan
HQ region
Asia

Offices2 records

Markets served

TaiMed Biologics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Trogarzo Product Sales: Revenue from global sales of Trogarzo (ibalizumab) through licensing and distribution partnerships in various territories including US, Europe, MENA, Asia regions.
  2. CDMO Services: Contract development and manufacturing organization services providing cGMP manufacturing, process development, analytical method development and validation, formulation development, and monoclonal antibody stability testing for pharmaceutical clients.
  3. Licensing and Co-development Agreements: Revenue from licensing TMB-365/380 technology and potential co-development partnerships with global pharmaceutical companies for long-acting HIV therapy.

Go-to-market motion2 records

Distribution channels9 records

Marketing channels4 records

TaiMed Biologics product offering

Product offering

Core offering

TaiMed Biologics develops and commercializes monoclonal antibody therapeutics for HIV disease. Its commercial product Trogarzo (ibalizumab) is the world's first humanized monoclonal antibody approved by the US FDA for the treatment of multidrug-resistant HIV-1 infection. The company is advancing TMB-365/TMB-380, the world's first long-acting dual antibody HIV therapy administered every 8 weeks, and a CD4-targeted ADC platform. It also provides biologics CDMO services from its cGMP facility in Taiwan.

Product overview

TaiMed Biologics is a commercial-stage biopharmaceutical company that has developed and commercialized Trogarzo® (ibalizumab), the world's first and only FDA-approved monoclonal antibody for HIV treatment. The company offers two formulations of Trogarzo: IV Infusion and IV Push. Its pipeline includes TMB-365, a second-generation antibody, TMB-380, a broadly neutralizing antibody, and their combination therapy TMB-365/TMB-380 (currently in Phase 2b), representing the world's first long-acting dual antibody HIV therapy. The company is also developing an innovative Antibody-Drug Conjugate (ADC) platform for HIV treatment. In addition to its proprietary products, TaiMed provides comprehensive CDMO (Contract Development and Manufacturing Organization) services from its cGMP facility in Taiwan.

Differentiator

Problem solved

Functional benefit

Brands

  • Trogarzo: First humanized monoclonal antibody (mAb) developed for the treatment of HIV-1 infection, approved by US FDA in 2018
  • CDMO Services

Products and services

  • Trogarzo (ibalizumab) The world's first humanized monoclonal antibody (mAb) approved for the treatment of HIV-1 infection. Acts as a post-attachment inhibitor by binding to the second extracellular domain of the CD4 receptor, blocking HIV entry while preserving immune function. Indicated for heavily treatment-experienced adults with multidrug-resistant (MDR) HIV-1 infection.
  • Trogarzo IV Infusion Intravenous infusion formulation of Trogarzo administered every two weeks for the treatment of HIV multi-drug-resistant patients as a last-line therapy.
  • Trogarzo IV Push Rapid intravenous push administration option of Trogarzo approved by the FDA for both loading dose (2000mg) and maintenance dose (800mg), offering convenient administration in undiluted form.
  • TMB-365 Second-generation Trogarzo monoclonal antibody for HIV treatment and prevention. Exhibits enhanced potency, viral coverage, and half-life. Developed from CD4-targeted antibody technology licensed from Aaron Diamond AIDS Research Center with TaiMed holding exclusive global rights.
  • TMB-365/TMB-380 Combination Long-acting dual monoclonal antibody combination for HIV maintenance therapy combining TMB-365 and TMB-380. Administered as a single IV infusion every 8 weeks as a complete regimen. No susceptibility screening required before initiation and zero drug-drug interactions due to antibody-based mechanism not metabolized through liver.
  • CD4-Targeted Antibody-Drug Conjugates (ADCs) Precision targeting ADC technology combining monoclonal antibodies with high binding specificity to CD4+ T cells with antiretroviral drug payloads. Triple-action mechanism: serves as carrier for antiretroviral drugs, acts as HIV entry inhibitor, and provides precision antiretroviral activity. First-in-Class ADC platform for HIV treatment.
  • Biologics CDMO Services Contract Development and Manufacturing Organization services providing cGMP manufacturing, process development, analytical method development and validation, formulation development, and monoclonal antibody stability testing. Uses single-use technology with bioreactors from 50L to 2000L capacity at the Zhubei facility in Taiwan.

Quantifiable outcome

  • 94% of participants maintained HIV-1 RNA below 50 copies/mL at Week 24 in Phase 2a trial
  • +4 more outcomes

Companies that use TaiMed Biologics

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

TaiMed Biologics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

TaiMed Biologics partnerships and signals

Strategic signal

Partnerships

16 partnerships are on record, tiered core and minor.

  • Samsung BiologicscoreStrategic or Co-development Partner · 22 June 2026Supply agreement for pharmaceutical ingredients for TMB-365, a long-acting biologic candidate currently in development. Collaboration supports continued development and manufacturing needs of TMB-365, following TaiMed's completion of Phase 2b enrollment for TMB-365/380.
  • R-PharmminorChannel Partner/ Reseller/ Distributor · 1 December 2025Post-Approval Named Patient Program supply agreement for Trogarzo in Russia, providing access for patients with limited treatment options.
  • National Taiwan University (NTU) School of PharmacyminorStrategic or Co-development Partner · 10 June 2025MOU for internship and talent development program. 16-week internship program at TaiMed facilities equivalent to 13 academic credits, providing hands-on exposure to biotechnology and biopharmaceutical industries.
  • Helios Pharmaceutical Company LimitedcoreChannel Partner/ Reseller/ Distributor · 6 March 2025Strategic collaboration for commercialization of Trogarzo in Vietnam. Leading pharmaceutical local distributor committed to advancing patient access to innovative medicines and aligning Vietnam's healthcare system with global standards.
  • Marigold TherapeuticsminorStrategic or Co-development Partner · 5 March 2025Strategic investment in Marigold Therapeutics to advance ADC drug development. Marigold has core ADC technology platform with founding team experienced in ADC molecule development. Headquartered in Cayman Islands with R&D team being built in Taiwan.
  • Slim Pharmaceuticals (Pvt) LtdcoreChannel Partner/ Reseller/ Distributor · 24 February 2025Exclusive license agreement for Trogarzo in Sri Lanka. Leading distributor of high-quality pharmaceuticals established in 2011, headquartered in Sri Lanka.
  • US-based Biotechnology ClientcoreImplementation/ SI/ Consulting Partner · 29 October 2024First international CDMO contract from US client for manufacturing antibody drug for clinical trials. Demonstrates international recognition of TaiMed's CDMO service capabilities.
  • Orient EuroPharma Company Limited (OEP)coreChannel Partner/ Reseller/ Distributor · 20 May 2024Exclusive license agreement for Trogarzo commercialization in Taiwan. OEP pursues regulatory approval and commercial sales. Established in 1982, listed on Taiwan GreTai Securities Market (stock code: 4120), with global workforce exceeding 1,000 employees.
  • Wuzhou Drug International Trading Co., Ltd.coreChannel Partner/ Reseller/ Distributor · 10 May 2024Exclusive license agreement for Trogarzo in Hong Kong and Macau. Macau pharmaceutical company that has introduced more than ten blockbuster products into China within five years. BLA submitted to regulatory authorities.
  • AcedrA BioPharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 14 March 2024Exclusive license, commercialization and distribution agreement for Trogarzo in Middle East and North Africa region (Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Jordan, Egypt, Lebanon, Iraq, Libya, Tunisia, Algeria, Morocco, Sudan). Saudi-based company focused on orphan drugs and niche therapeutic segments.
  • WEP Clinical Ltd.minorChannel Partner/ Reseller/ Distributor · 1 January 2023Named Patient Program (NPP) collaboration for Trogarzo in Europe and regions beyond US and Canada. Professional services company helping patients obtain medications when no other treatment options are available.
  • Theratechnologies Inc.coreChannel Partner/ Reseller/ DistributorExclusive marketing partner for Trogarzo in United States and Canada. Partnership continues despite announcement of Future Pak acquisition of Theratechnologies expected to close Q4 2025.
  • Aaron Diamond AIDS Research Center (ADARC)coreStrategic or Co-development PartnerTechnology licensing for CD4-targeted antibody technology platform used in TMB-365 development. Led by Dr. David Ho.
  • National Institutes of Health (NIH)coreStrategic or Co-development PartnerNon-exclusive licensing agreement from NIAID for TMB-380 (VRC07-523LS), a broadly neutralizing HIV-1 antibody. NIH conducted successful Phase 1 trial demonstrating efficacy in HIV patients receiving bi-monthly IV infusion.
  • The Rockefeller UniversityminorStrategic or Co-development PartnerResearch partnership for HIV antibody development and technology advancement.
  • Tanvex BioPharma IncminorStrategic or Co-development PartnerCollaboration with biotech and medical institutions for research and development of technologies promoting human well-being.

Scale indicators14 records

Recent moves8 records

Expansion highlights6 records

TaiMed Biologics competitors and assessment

Company assessment

Direct peers

  • ViiV Healthcare: Majority-owned by GSK, ViiV is the leading global HIV-focused pharmaceutical company with long-acting injectables like Cabenuva (cabotegravir/rilpivirine) and Apretude. It is the most direct competitor to TaiMed's TMB-365/380 in the long-acting HIV maintenance therapy space.
  • Theratechnologies: Exclusive marketing partner for Trogarzo in US/Canada. Theratechnologies is a specialty HIV-focused company developing Trogarzo and other HIV therapeutics, with deep domain overlap though it functions as a commercial rather than R&D peer for TaiMed.

Emerging players

  • CytoDyn: Clinical-stage biotech developing leronlimab, a CCR5-targeting mAb, for HIV and other indications. CytoDyn is an emerging mAb-focused HIV therapeutic developer with comparable niche positioning, though with different mechanism and clinical profile.

Broad incumbents

  • AbbVie: Diversified biopharmaceutical company with a strong immunology and infectious disease portfolio. AbbVie's expertise in mAb development and commercialization (Humira, Skyrizi) makes it a relevant peer and potential acquirer for TaiMed's mAb platform.
  • Gilead Sciences: Largest HIV franchise globally with Biktarvy, Descovy, and the recently approved long-acting capsid inhibitor lenacapavir (Sunlenca). Gilead is both a competitor in long-acting HIV and a potential acquirer/licensor for TaiMed's TMB-365/380 platform.
  • Merck & Co. Major HIV therapy player with doravirine (Pifeltro) and ongoing development of once-monthly oral islatravir combinations. Merck's combination therapies compete in the same maintenance therapy market TaiMed targets with TMB-365/380.
  • Lonza Group: Largest global CDMO with extensive biologics manufacturing capabilities. Lonza is a relevant peer for TaiMed's growing CDMO business, providing scale benchmarks in cGMP contract manufacturing for monoclonal antibodies.
  • WuXi Biologics: Leading global biologics CDMO providing end-to-end mAb development and manufacturing services. WuXi is a direct competitor for TaiMed's CDMO service business and shares exposure to mAb manufacturing scale-up.
  • Regeneron Pharmaceuticals: Leading mAb development platform (VelocImmune) with deep expertise in antibody engineering, similar to TaiMed's proprietary antibody engineering capabilities (LM52 glycan, histidine modification). Relevant as a technology platform peer.

Others

  • Samsung Biologics: Global CDMO partner for TaiMed's TMB-365 supply. Samsung Biologics is one of the world's largest contract manufacturers and a relevant peer in the CDMO services space where TaiMed increasingly competes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

TaiMed Biologics social profiles

Digital presence

TaiMed Biologics compliance and trust

Trust signal

Compliance3 records

TaiMed Biologics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TaiMed Biologics leadership team

Management profile

Number of profiles

Profiles6 records

TaiMed Biologics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TaiMed Biologics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TaiMed Biologics

What does TaiMed Biologics do?

TaiMed Biologics develops and commercializes monoclonal antibody therapeutics for HIV disease. Its commercial product Trogarzo (ibalizumab) is the world's first humanized monoclonal antibody approved by the US FDA for the treatment of multidrug-resistant HIV-1 infection. The company is advancing TMB-365/TMB-380, the world's first long-acting dual antibody HIV therapy administered every 8 weeks, and a CD4-targeted ADC platform. It also provides biologics CDMO services from its cGMP facility in Taiwan.

Is TaiMed Biologics a public or private company?

TaiMed Biologics is a public company. It is classified as public and is currently operating.

When was TaiMed Biologics founded?

TaiMed Biologics was founded in 2007. It employs 51 to 100 people.

Where is TaiMed Biologics based?

TaiMed Biologics is headquartered in Taipei, Taiwan, in the Asia region.

How does TaiMed Biologics make money?

Three revenue lines are on record. Trogarzo Product Sales are the primary driver. The others are CDMO Services and licensing and Co-development Agreements.

Who are TaiMed Biologics's main competitors?

Direct peers on record are ViiV Healthcare and Theratechnologies. CytoDyn is listed as an emerging player. Broad incumbents are AbbVie, Gilead Sciences, Merck & Co., Lonza Group, WuXi Biologics and Regeneron Pharmaceuticals. Samsung Biologics is listed as an others.

Does TaiMed Biologics have an API?

No public API is recorded for TaiMed Biologics.

What industry is TaiMed Biologics in?

TaiMed Biologics's product category is HIV Therapeutics Biologics. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAKAGAB, HIV/AIDS Medicine. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewTaiMed Biologics to Present 24-Week Phase 2a Data on TMB-365/TMB-380 Maintenance Regimen at HIV Glasgow 2026TaiMed Biologics will present 24-week Phase 2a data on its TMB-365/TMB-380 maintenance regimen at HIV Glasgow 2026, administered every eight weeks in virologically suppressed HIV-1 patients. The company will also present an encore poster on its Phase 1 single-dose escalation study of TMB-365.GlobeNewswireTaiMed Biologics to Present 24-Week Phase 2a Data on TMB-365/TMB-380 Maintenance Regimen at HIV Glasgow 2026TaiMed Biologics will present 24-week Phase 2a data on its TMB-365/TMB-380 maintenance regimen at HIV Glasgow 2026, which runs November 8–11 in Glasgow. The study evaluated the q8w antibody combination for maintaining viral suppression in HIV-1 patients switching from combination antiretroviral therapy. The company also plans an encore poster on its Phase 1 single-dose escalation study.Business & FinancialTaimed Biologics To Present 24-Week Phase 2A Data On TMB-365/TMB-380 Maintenance Regimen At HIV Glasgow 2026TaiMed Biologics will present 24-week Phase 2a data on its TMB-365/TMB-380 maintenance regimen at HIV Glasgow 2026, scheduled November 8–11 in Glasgow. The study evaluated the q8w antibody combination for maintaining viral suppression in HIV-1 patients switching from combination antiretroviral therapy. The company also plans an encore poster on its Phase 1 single-dose escalation study.Business & FinancialTaimed Biologics Reports Idweek 2026 Data Highlighting TMB-365 And Its Potential Across Long-Acting HIV CombinationsTaiMed Biologics presented IDWeek 2026 data on TMB-365, a CD4-targeted antibody, showing antiviral activity and safety in a Phase 1 study. Laboratory susceptibility findings support its complementary activity with TMB-380, and an ongoing Phase 2b study is expected to report interim results by year-end 2026.YahooTaiMed Biologics Reports IDWeek 2026 Data Highlighting TMB-365 and Its Potential Across Long-Acting HIV CombinationsTaiMed Biologics presented Phase 1 data for TMB-365 at IDWeek 2026, showing antiviral activity and tolerability in 25 HIV-positive participants. The antibody reduced HIV-1 RNA by 1.55-1.57 log10 copies/mL at 400-800 mg doses, with no serious adverse events. Lab susceptibility data support its use in combination with TMB-380.GlobeNewswireTaiMed Biologics Reports IDWeek 2026 Data Highlighting TMB-365 and Its Potential Across Long-Acting HIV CombinationsTaiMed Biologics presented Phase 1 data for TMB-365 at IDWeek 2026, showing antiviral activity and tolerability in 25 HIV-positive participants. The antibody reduced HIV-1 RNA by 1.55-1.57 log10 copies/mL and retained activity against variants resistant to TMB-380, supporting its use in combination regimens.GlobeNewswireTaiMed Biologics to Present Oral and Poster Presentations on TMB-365 and TMB-365/TMB-380 Combination Therapy at IDWeek 2026TaiMed Biologics will present clinical data on TMB-365 and in vitro susceptibility data for the TMB-365/TMB-380 combination at IDWeek 2026 in Washington, D.C. The presentations cover a single-dose escalation study and resistance evaluation in suppressed HIV-1 patients. The company aims to advance its long-acting antibody-based HIV treatment.BioSpaceTaiMed Biologics (4147) Receives TFDA Drug License Collection Notice for Trogarzo, Marking the Final Step Toward Commercial Launch in TaiwanTaiMed Biologics received a TFDA Drug License Collection Notice for Trogarzo, the final step toward its commercial launch in Taiwan. The company expects the drug to be launched after Orient EuroPharma completes licensing procedures. TaiMed is also advancing its long-acting HIV therapy TMB-365/380, with Phase 2b trial completion in May 2026.Investing.comTaiMed’s HIV therapy Trogarzo receives Taiwan drug license notice By Investing.comTaiMed Biologics announced that its HIV therapy Trogarzo has received a Drug License Collection Notice from the Taiwan Food and Drug Administration, with commercialization partner Orient EuroPharma set to complete procedures to obtain the license. Trogarzo is indicated for adults with multidrug-resistant HIV-1 infection who are heavily treatment-experienced and whose current antiretroviral regimen is failing. The companies entered into an exclusive commercialization agreement for the Taiwan market in May 2024, with TaiMed responsible for product supply and Orient EuroPharma handling regulatory registration, marketing, and commercialization.GlobeNewswireTaiMed Biologics (4147) Receives TFDA Drug License Collection Notice for Trogarzo, Marking the Final Step Toward Commercial Launch in TaiwanTaiMed Biologics announced it has received the Drug License Collection Notice from Taiwan's Food and Drug Administration (TFDA) for its HIV therapy Trogarzo (ibalizumab), the world's first and only CD4-directed monoclonal antibody approved for treating multidrug-resistant HIV-1 infection. Its commercialization partner, Orient EuroPharma, will complete the remaining procedures to obtain the drug license, marking the final step toward official commercial launch in Taiwan. TaiMed, which achieved profitability in Q1 2026 and continues to advance its next-generation long-acting HIV therapy TMB-365/380 (estimated peak annual sales of US$3–4 billion), noted that while Trogarzo targets the smaller salvage-treatment market, it provides stable revenue contributions to the company.